Systemic gene delivery to the central nervous system using Adeno-associated virus
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV)-mediated gene delivery has emerged as an effective and safe tool for both preclinical and clinical studies of neurological disorders. The recent discovery that several serotypes are able to cross the blood-brain barrier when administered systemically has been a real breakthrough in the field of neurodegenerative diseases. Widespread transgene expression after systemic injection could spark interest as a therapeutic approach. Such strategy will avoid invasive brain surgery and allow non-focal gene therapy promising for CNS diseases affecting large portion of the brain. Here, we will review the recent results achieved through different systemic routes of injection generated in the last decade using systemic AAV-mediated delivery and propose a brief assessment of their values. In particular, we emphasize how the methods used for virus engineering could improve brain transduction after peripheral delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135 · cited 1×
“In this particular disorder, brain pathology can be detected in utero and death occurs within the two first years of age (Sidransky et al., 2009).”
BackgroundAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 3×
“Intravenous administration of rAAV9 to neonatal rats showed up to 78% of transduction of motor neurons of the spinal cord associated with widespread CNS transduction (Wang et al., 2010).”
BackgroundXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 2×
“REVIEW ARTICLE published: 02 June 2014 doi: 10.3389/fnmol.2014.00050 Systemic gene delivery to the central nervous system using”
BackgroundMethodInfluentialAstrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons
Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., & Przedborski, S. (2007) · Nature Neuroscience · doi:10.1038/nn1876 · Cited by 1,220
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872 · cited 1×
“…Institute at Nationwide Children’s Hospital, USA *Correspondence: Benjamin Dehay, Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France e-mail: benjamin.dehay@u-bordeaux.fr †Erwan Bezard and Benjamin Dehay are senior authors.”
BackgroundFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 2×
“Moreover, the capsid but not the ITR sequence influences cell and tissue tropism (Grimm et al., 2008; Vandenberghe et al., 2008).”
BackgroundDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 2×
“…from the European Commission (to Benjamin Dehay); by a grant from the Fondation pour la Recherche Médicale (to Benjamin Dehay); by Agence Nationale de la Recherche Grants ANR-08-MNP-018 and ANR-07-MNPTrafinlid (to Erwan Bezard) and Mathieu Bourdenx is a recipient of an MESR fellowship.”
BackgroundMethodGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696 · cited 3×
“This work was supported by Marie Curie Reintegration Grant FP7-PEOPLE-2009-ERG256303 from the European Commission (to Benjamin Dehay); by a grant from the Fondation pour la Recherche Médicale (to Benjamin Dehay); by Agence Nationale de la Recherche Grants ANR-08-MNP-018 and ANR-07-MNPTrafinlid (to Erwan Bezard) and Ma…”
BackgroundZhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547 · cited 3×
“Glycans with terminal β-galactose linkages have been recently identified as the primary receptor for AAV9 (Bell et al., 2011; Shen et al., 2011).”
BackgroundDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 2×
“…from the European Commission (to Benjamin Dehay); by a grant from the Fondation pour la Recherche Médicale (to Benjamin Dehay); by Agence Nationale de la Recherche Grants ANR-08-MNP-018 and ANR-07-MNPTrafinlid (to Erwan Bezard) and Mathieu Bourdenx is a recipient of an MESR fellowship.”
BackgroundMethodDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 1×
“REVIEW ARTICLE published: 02 June 2014 doi: 10.3389/fnmol.2014.00050 Systemic gene delivery to the central nervous system using”
InfluentialGray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · cited 10×
“However, with regard to these discrepancies between studies, a high-titer dose of viral particles appeared to be the common denominator for monkey injection (Bevan et al., 2010; Gray et al., 2011b; Dehay et al., 2012; Mattar et al., 2012; Samaranch et al., 2012).”
BackgroundResultInfluentialSamulski, R. J., Berns, K. I., Tan, M., & Muzyczka, N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2077 · Cited by 466
Gray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398 · cited 1×
“F) has been reported to reduce proteasomal degradation of viral particles and therefore enhance retina transduction after either systemic or intravitreous injection of rAAV2, -8, or -9 (Petrs-Silva et al., 2008; Zhong et al., 2008; Dalkara et al., 2011).”
BackgroundOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355 · cited 5×
“To overcome this concern, Katherine A. High’s group developed an empty mutant capsid, which can interact with antibodies without entering the cell (Mingozzi et al., 2013).”
BackgroundInfluentialAdeno-associated virus general transduction vectors: analysis of proviral structures
McLaughlin, S. K., Collis, P., Hermonat, P. L., & Muzyczka, N. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1963-1973.1988 · Cited by 348 · cited 2×
“The first recombinant AAVs of serotype 2 (rAAV2) have been generated in the 1980s after the removal of 96% of the viral genome (Samulski et al., 1982; Hermonat and Muzyczka, 1984; McLaughlin et al., 1988).”
BackgroundMethodInfluentialAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345
Bevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L., Schmelzer, L., Chan, C. M., McCrate, M., Chicoine, L. G., Coley, B. D., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.157 · Cited by 337
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305
Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299 · cited 8×
“However, with regard to these discrepancies between studies, a high-titer dose of viral particles appeared to be the common denominator for monkey injection (Bevan et al., 2010; Gray et al., 2011b; Dehay et al., 2012; Mattar et al., 2012; Samaranch et al., 2012).”
BackgroundResultInfluentialZhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291 · cited 12×
“The 37/67-kDa laminin receptor has been identified as co-receptor for AAVs of serotypes 2, 3, 8, and 9; however, its involvement in BBB crossing has not been determined yet (Akache et al., 2006).”
BackgroundInfluentialThe AAV9 receptor and its modification to improve in vivo lung gene transfer in mice
Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G.-P., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57367 · Cited by 190 · cited 2×
“…from the European Commission (to Benjamin Dehay); by a grant from the Fondation pour la Recherche Médicale (to Benjamin Dehay); by Agence Nationale de la Recherche Grants ANR-08-MNP-018 and ANR-07-MNPTrafinlid (to Erwan Bezard) and Mathieu Bourdenx is a recipient of an MESR fellowship.”
BackgroundGray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185 · cited 3×
“…from the European Commission (to Benjamin Dehay); by a grant from the Fondation pour la Recherche Médicale (to Benjamin Dehay); by Agence Nationale de la Recherche Grants ANR-08-MNP-018 and ANR-07-MNPTrafinlid (to Erwan Bezard) and Mathieu Bourdenx is a recipient of an MESR fellowship.”
BackgroundMethodTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155 · cited 4×
“Moreover, the capsid but not the ITR sequence influences cell and tissue tropism (Grimm et al., 2008; Vandenberghe et al., 2008).”
BackgroundMethodInfluentialThe advent of AAV9 expands applications for brain and spinal cord gene delivery
Dayton, R. D., Wang, D. B., & Klein, R. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.681463 · Cited by 144 · cited 2×
“Adeno-associated virus is a non-pathogenic dependovirus from the parvoviridae family requiring helper functions from other viruses, such as adenovirus or herpes simplex virus, to fulfill its life cycle (Dayton et al., 2012).”
BackgroundMethodInfluentialInsertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus
Rabinowitz, J. E., Xiao, W., & Samulski, R. J. (1999) · Virology · doi:10.1006/viro.1999.0045 · Cited by 136 · cited 2×
“…from the European Commission (to Benjamin Dehay); by a grant from the Fondation pour la Recherche Médicale (to Benjamin Dehay); by Agence Nationale de la Recherche Grants ANR-08-MNP-018 and ANR-07-MNPTrafinlid (to Erwan Bezard) and Mathieu Bourdenx is a recipient of an MESR fellowship.”
BackgroundMcCarty, D. M., DiRosario, J., Gulaid, K., Muenzer, J., & Fu, H. (2009) · Gene Therapy · doi:10.1038/gt.2009.85 · Cited by 105
Adeno-associated Virus: A Key to the Human Genome?
Henckaerts, E., & Linden, R. M. (2010) · Future Virology · doi:10.2217/fvl.10.48 · Cited by 71
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“For example, the CMV promoter has been shown to be silenced in the central nervous system (CNS) [16].”
BackgroundInfluentialBlood–brain barrier shuttle peptides: an emerging paradigm for brain delivery
Oller-Salvia, B., Sánchez-Navarro, M., Giralt, E., & Teixidó, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 442
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Rational design of a compact CRISPR-Cas9 activator for AAV-mediated delivery
Vora, S., Cheng, J., Xiao, R., VanDusen, N. J., Quintino, L., Pu, W. T., Vandenberghe, L. H., Chavez, A., & Church, G. (2018) · doi:10.1101/298620 · Cited by 42
DNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations
Schnödt, M., Schmeer, M., Kracher, B., Krüsemann, C., Espinosa, L. E., Grünert, A., Fuchsluger, T., Rischmüller, A., Schleef, M., & Büning, H. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.60 · Cited by 39
Metadata
- Authors
- Bourdenx, M., Dutheil, N., Bezard, E., & Dehay, B.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-06-02
- Volume
- 7
- Pages
- 50-50
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2029835792
- Cited by
- 79
- References
- 35
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.